Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860975 | 0.91 | MAPK1 (0.34) | CYP19A1CA1CA2NAMPTMAPK1 | |
| SCHEMBL5322672 | 0.86 | CASP1 (0.37) | TDP1FAAHCA1CA2NPSR1 | |
| SCHEMBL4862019 | 0.81 | MEN1 (0.37) | NPSR1NAMPTMAPK1IDO1KDM4E | |
| SCHEMBL4865746 | 0.73 | NPSR1 (0.37) | TDP1CYP19A1NPSR1MAPK1PKM | |
| SCHEMBL14224313 | 0.73 | NPSR1 (0.37) | TDP1CYP19A1NPSR1MAPK1PKM | |
| SCHEMBL5225649 | 0.66 | POLB (0.38) | NAMPTKDM4E | |
| SCHEMBL5318595 | 0.66 | NPC1 (0.37) | MAPK1IDO1 | |
| SCHEMBL14196720 | 0.66 | MAPK1 (0.38) | CYP19A1NPSR1NAMPTMAPK1KDM4E | |
| SCHEMBL4860414 | 0.66 | MAPK1 (0.38) | CYP19A1NPSR1NAMPTMAPK1KDM4E | |
| SCHEMBL14196718 | 0.65 | NPSR1 (0.40) | TDP1FAAHCA1CA2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | MUSICKI BRANISLAV | 2007-08-16 | — | — | US | disclosed |
| US-20040097490-A1 | Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097490-A1 | Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials | GAA, BBOX1, BPGM | TDP1 2204/4885CYP19A1 535/4885FAAH 571/4885 |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | GAA, PEPD, MGAM | TDP1 2627/4885CYP19A1 745/4885FAAH 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.